CZECRIN at the Brno Oncology Days
“The year 2022 brings fundamental changes in the conduct of clinical trials (not only) in the Czech Republic” – The topic of the CZECRIN/PharmAround workshop, which was presented at the 46th Brno Oncology Days (BOD) on 12-14 October 2022.
The first lecture was given by Beata Čečetková, M.D., Ph.D. She presented the results of the current study of the Association of Innovative Pharmaceutical Industry (AIFP) focused on the overview of clinical trials of pharmaceutical products in the Czech Republic. The study showed that in 2021, AIFP member companies conducted 396 clinical trials, mainly in the field of oncology, infectious diseases and diseases of the nervous system.
Representatives of Dubanská&co attorney’s office conducted the second lecture focused on the new legislation in the field of clinical trials. The third part of the workshop was presented by Radka Obermannová, M.D., Ph.D., Head of Phase-I Studies (“First in human trials”) at the Masaryk Memorial Cancer Institute. She mentioned the 10year anniversary of this unit and compared the situation ten years ago and nowadays.
The topic of the last lecture “Challenges for clinical trials or it won’t work without collaboration” belonged to Associate Professor Regina Demlova, M.D., Ph.D. “Thanks to high quality data sources, very good relations between doctors and patients and especially thanks to intensive cooperation between all participants in clinical studies is the clinical trials in the Czech Republic at a high level. Collaboration is absolutely essential for the successful implementation of a clinical study,” Demlová summarised.
She also reminded the International Clinical Trials Day which is celebrated every year on May 20 in honor of the first controlled study made by the Scottish doctor James Lind in 1747.